P/E at 35.15 vs Industry's 33.42: What the Data Shows for Sun Pharmaceutical Industries Ltd

Valuation Picture: Premium Amidst Sector Norms

The current P/E of 35.15 for Sun Pharmaceutical Industries Ltd stands above the industry average of 33.42, indicating a valuation premium of approximately 5.2%. This premium suggests that investors are willing to pay slightly more for the stock relative to its peers in the Pharmaceuticals & Biotechnology sector, which may reflect expectations of superior earnings stability or growth prospects. However, the premium is not excessive when compared to some other large-cap pharmaceutical companies, which often trade at multiples well above 40x. The market capitalisation of Rs 4,26,830 crores firmly places the company in the large-cap category, reinforcing its stature within the sector.

Performance Across Timeframes: Divergent Momentum

Examining the stock’s returns across various timeframes reveals a nuanced picture. Over the past year, Sun Pharmaceutical Industries Ltd has declined by 3.18%, slightly outperforming the Sensex’s 4.30% fall. This relative resilience is noteworthy given the sector’s mixed performance. More strikingly, the stock has gained 11.10% over the last three months, a period during which the Sensex declined by 6.66%. This divergence suggests a recent acceleration in buying interest or positive developments specific to the company or its industry segment. However, the one-month return of 0.83% lags behind the Sensex’s 6.73%, indicating some short-term volatility or profit-taking after the strong quarterly gains — is this a temporary pause or a sign of consolidation ahead?

Moving Average Configuration: Bullish Across All Key Levels

The technical setup for Sun Pharmaceutical Industries Ltd is robust, with the stock trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. This alignment across short, medium, and long-term moving averages typically signals a sustained uptrend and strong underlying momentum. The stock is currently just 4.08% below its 52-week high of Rs 1850.95, underscoring its proximity to recent peak levels. However, it has experienced a slight pullback of 0.39% today, following three consecutive days of gains, which may reflect short-term profit booking or sector-wide fluctuations — is this a genuine recovery or a dead-cat bounce?

Relative Performance vs Sensex: Outperformance in Most Periods

When compared to the Sensex, Sun Pharmaceutical Industries Ltd has demonstrated consistent outperformance over multiple time horizons. The stock’s 1-week return of 5.49% contrasts with the Sensex’s decline of 1.13%, while the year-to-date gain of 3.04% stands in stark contrast to the Sensex’s 9.89% loss. Over longer periods, the stock’s 3-year return of 79.57% and 5-year return of 170.66% significantly outpace the Sensex’s 25.65% and 57.41% respectively. However, the 10-year return of 118.41% trails the Sensex’s 199.88%, reflecting a period of relative underperformance in the distant past. This pattern suggests that the company has been a strong performer in recent years, but investors may want to consider how this aligns with their investment horizon — should investors in Sun Pharmaceutical Industries Ltd hold, buy more, or reconsider?

Sector Context: Pharmaceuticals & Biotechnology Showing Strength

The Pharmaceuticals & Biotechnology sector has seen positive results from all three companies that have declared earnings recently, with no flat or negative outcomes reported. This broad-based positivity within the sector provides a supportive backdrop for Sun Pharmaceutical Industries Ltd. The sector’s overall health may be contributing to the stock’s recent outperformance, especially over the last three months. The company’s performance today is inline with the sector, despite a minor decline of 0.39%, which is less severe than the Sensex’s 0.91% drop. This relative stability amid sector strength may be a factor in the stock’s current valuation premium.

Rating Reassessment: Previously Hold, Now Updated

Sun Pharmaceutical Industries Ltd was previously rated Hold by MarketsMOJO before its rating was updated on 27 Apr 2026. While the current rating is not disclosed, the reassessment reflects a fresh evaluation of the company’s fundamentals, valuation, and technicals. The previous Hold rating was based on a Mojo Score of 72.0, indicating a moderately positive outlook. The updated rating likely incorporates the recent strong technical configuration and the stock’s relative outperformance — what is the current rating?

Conclusion: A Balanced Valuation with Strong Technicals and Mixed Performance

The data for Sun Pharmaceutical Industries Ltd paints a picture of a stock trading at a modest premium to its sector, supported by a strong technical setup with prices above all major moving averages. Its recent three-month surge contrasts with a modest one-year decline, highlighting shifting momentum that investors may want to monitor closely. The company’s relative outperformance against the Sensex across most timeframes, combined with positive sector results, adds further context to its valuation. The rating update from a previous Hold suggests a reassessment of these factors — should investors in Sun Pharmaceutical Industries Ltd hold, buy more, or reconsider?

Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today